Found 141 studies with search of: Forest LaboratoriesReview the 141 active clinical trials (on clinicaltrials dot gov) and you'll see how strong their pipeline is.Their recent FDA approvals plus extremely strong cash position / balance sheet should command a much higher stock price going forward.FRX is a rare gem.
I work at Forest. There may be many products in the pipeline, but very few are going to make it to market.Also, the patent for Lexapro is due to expire in 2011.
Not sure which 'pipeline' you are looking at???This is directly from site- note there are only about 5 http://www.frx.com/research/pipeline.aspx